Table 6

Ongoing clinical trials of therapies affecting DNA damage repair pathways that include patients with pancreatic cancer

NCT02950064Phase I trial, open-labelBRCA-mutated pancreatic, ovarian, triple-negative breast or prostate cancers or solid tumours with other DDR mutationsBTP-114, a novel platinum productActive, not recruiting
NCT01489865Phase I/II trial, single armPDAC with BRCA mutation or personal or family history of hereditary breast or ovarian cancerABT-888 (a new PARP inhibitor) with mFOLFOX6Active, not recruiting
NCT01585805Phase II, open-label, randomisedMetastatic or locally advanced BRCA-mutated PDACVeliparib alone vs gemcitabine/cisplatin vs veliparib and gemcitabine/cisplatinActive, not recruiting
NCT02498613Phase II trial, single armAdvanced solid tumours with failure to at least one line of standard systemic treatmentOlaparib+cediranib (anti-VEGF)Recruiting
NCT03162627Phase I/IIRefractory advanced cancerOlaparib+selumetinib (anti-MEK)Recruiting
NCT03404960Phase Ib/II, open-label, randomisedMetastatic or locally advanced PDAC, with 16 weeks of platinum-based treatment without progressionNiraparib+nivolumab‚ÄČor ipilimumabRecruiting
NCT02630199Phase I, open-labelAdvanced, refractory cancerPaclitaxel and AZD6738 (ATR inhibitor)Recruiting
NCT02223923Phase I, single groupSolid tumour refractory to conventional treatmentAZD6738 (ATR inhibitor) with radiotherapyRecruiting
NCT03669601Phase I, non-randomisedLocally advanced or metastatic solid tumour that has progressed on standard therapyAZD6738 and gemcitabineRecruiting
NCT02264678Phase I, two-part, open-labelSolid malignant tumour that is not considered appropriate for further standard treatmentAZD6738 with different drugs, including carboplatin and olaparibRecruiting
NCT03682289Phase IILocally advanced or metastatic solid tumour malignancy, including any pancreatic cancersAZD6738 alone or in combination with olaparibRecruiting
NCT02576444Phase IIMetastatic progressive cancerPatients with HRD will be treated with olaparib and AZD6738Active, not recruiting
NCT02723864Phase I, single groupMetastatic cancer with previous fail to survival prolonging therapiesVeliparib+cisplatin+VX-970 (ATR inhibitor)Recruiting
NCT02595931Phase I, single groupMetastatic or unresectable malignancy that is refractory to standard therapy or for which no standard therapy exists and where irinotecan is deemed a reasonable treatment optionVX-970 and irinotecanRecruiting
NCT02588105Phase ILocally advanced/metastatic cancer that is refractory or resistant to standard therapy, or have no effective standardAZD0156+olaparib, AZD0156+irinotecan/FOLFIRIActive, not recruiting
NCT02194829Phase IA phase I and randomised phase II study of nab-paclitaxel/gemcitabine with or without AZD1775 for treatment of metastatic adenocarcinoma of the pancreasNab-paclitaxel/gemcitabine
Active, not recruiting
  • FOLFIRI, folinic acid, fluouracil, irinotecan; FOLFOX, folinic acid, fluouracil, oxaliplatin; nab, nanosized albumin-bound; PDAC, pancreatic ductal adenocarcinoma.